Publications >> Original Articales in Journals
Original articles in journals

Original Articles in Journals

Wilder-Smith CH, Raue F, Holz F, Ziegler R. Procollagen-III Peptid als Verlaufsparameter bei M. Paget des Knochens. Verh Dtsch Gsell Inn Med 1983;3243-4, Wiesbaden
Wilder-Smith CH, Raue F, Holz F, Ziegler R. Procollagen-III peptide serum levels in Paget`s disease of bone. Klin Wschr 1987;65:174-8
Wilder-Smith CH. Schmerztherapie bei Tumorpatienten. Arzneimitteltherapie 1987;5:139-151
Wilder-Smith CH, Heimgartner D, Senn HJ. Retard Morphin und Buprenorphine zur Prophylaxe und Therapie starker Schmerzen bei Tumorpatienten. Schweiz Med Wschr 1987;117(Suppl 22):27
Wilder-Smith CH, Senn HJ. Opioide in der Tumorschmerztherapie. Gazette Medicale 1988;9:9-19
Wilder-Smith CH, Senn HJ. Der Schmerz bestimmt die Therapieform. Gazette Medicale 1988; 10:79-83
Merki HS, Wilder-Smith CH, Halter F. Treatment with H2-receptor antagonists: when is the best time to dose? Scand J Gastroenterol 1988;23(suppl 153):15-22
Wilder-Smith CH, Senn HJ. Anti-emetic prophylaxis of cancer chemotherapy-induced nausea and vomiting with cinnarizine and lorazepam. Oncology 1989;46:169-172
Wilder-Smith CH. Morphinmetabolismus bei Niereninsuffizienz, in: Chronischer Schmerz - Therapiekonzepte, U. Dethlefsen (ed), Springer Verlag, Heidelberg 1989;129-135 (book)
Wilder-Smith C, Schimke J, Vergin L, Senn HJ. Long-acting metoclopramide: suitability for prophylaxis of chemotherapy-induced delayed nausea and vomiting. Drug Research/ Arzneimittelforschung 1989;39:1164-1167
Naji P, Farschtschian M, Wilder-Smith O and Wilder-Smith CH. Epidural droperidol and morphine for post-operative pain. Anesth Analg 1990;70:583-588
Merki HS, Halter F, Wilder-Smith CH, Allemann P, Witzel L, Kempf M, Röhmel J, Walt RP. The effect of food on the efficacy of H2-receptor antagonists in duodenal ulcer patients and normal subjects. Gut 1990;31:148-150
Wilder-Smith CH, Halter F, Merki HS. The effect of different dosing regimens of the long-acting H2-receptor antagonist sufotidine on intragastric acidity. Eur J Gastroenterol Hepatol 1990;2:373-377
Wilder-Smith CH, Schuler L, Osterwalder B, Naji P, Senn HJ. Patient-controlled antiemesis for chemotheraoy-induced nausea and vomiting. J Pain Symptom Management 1990:5:375-378
Wilder-Smith C, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990;35:976-983
Kaufmann D, Wilder-Smith CH, Halter F, Merki HS. Cigarette smoking, gastric acidity and peptic ulceration. What are the relationships? Dig Dis Sci 1990;35:1482-1487
Röhmel J, Merki HS, Wilder-Smith CH, Walt RP. Analysis and statistical evaluation of continuous pH recordings. Dig Dis 1990;8(suppl 1)87-96
Wilder-Smith CH, Halter F, Ernst T, Gennoni M, Zeyen B, Varga L, Röhmel JJ, Merki HS. Rapid loss of acid suppression of H2-receptor antagonists. Aliment Pharmacol Therap 1990:4(suppl 1):15-27
Merki HS, Hunt RH, Walt RP, Wilder-Smith CH, Gennoni M, Ernst T, Zeyen B, Röhmel J, Halter F. A new programmable infusion pump for individual control of intragastric pH: validation and effect of ranitidine. Eur J Gastroenterol Hepatol 1991;3:9-13
Wilder-Smith, CH. Die Auswahl des Opioids: Schmerztherapie in der Onkologie. In: Grundlagen und Praxis der Behandlung mit Opiaten. Eds.: Adler R, Frei E. Recom Publishing, Basle; 1991 (book)
Merki HS, Wilder-Smith CH, Gwerder J, Groß J. Safety aspects of ambulant esophageal manometry and pH-monitoring. Dig Dis Sci 1991;36(suppl):29-32
Merki HS, Wilder-Smith CH, Walt RP, Halter F. The cephalic and gastric phases of secretion during H2-antagonist treatment. Gastroenterology 1991;101:599-606
Wilder-Smith CH, Merki HS. Is the time of dosing with a potent, long-acting H2-receptor antagonist critical? Studies with SKF-94482. Scand J Gastroenterol 1991;26:501-507
Schmid L, Jeschko M, Wilder-Smith C, Schafroth U, Thürlimann B, Pedrazzini A, Senn HJ. Ceftriaxone and Amikacin versus Ceftazidime and Amikacin in febrile granulocytopenia. Chemotherapy 1991;37:346-352
Halter F, Wilder-Smith CH. Gastrin: Friend or foe of peptic ulcer disease? J Clin Gastroenterol 1991;13(suppl 1):575-582
Wilder-Smith CH, Merki HS. Tolerance and rebound to H2-receptor antagonists: patients with duodenal ulcer and healthy controls. Dig Dis Sci 1991;36:1685-1690
Wilder-Smith CH. Schmerzen bei Tumorpatienten: Kriterien zur Auswahl des Opioides. Therapiewoche 1991;11:781-786
Wilder-Smith CH, Schimke J, Osterwalder B, Schuler L, Senn HJ. Cinnarizine for oral antiemetic prophylaxis of platin chemotherapy-induced nausea and vomiting. Acta Oncologica 1991;30:731-734
Wilder-Smith CH, Merki HS. Antisecretory agents in stress ulcer prophylaxis: A critical reappraisal. Eur J Gastroenterol Hepatol 1992;4:689-696
Wilder-Smith CH, Gennoni MA, Triller J, Scheurer U, Merki HS. Is fluoroscopic verification of electrode position necessary in ambulatory intragastric pH-monitoring? Digestion 1992;52:1-5
Wilder-Smith CH, Halter F, Häcki W, Merki HS. Gastric acidity and hormones: comparison of fixed-dose and pH-feedback controlled infusions of ranitidine. Brit J Clin Pharmacol 1992;33:487-493
Wilder-Smith CH, Meier-Ruge W, Scheurer U, Nöthiger F, Merki HS. Colonic neuronal dysplasia: an ignored cause of chronic constipation in adults? Eur J Gastroenterol Hepatol 1992;4:679-682
Wilder-Smith CH, Schuler L. Postoperative analgesia: pain by choice? The influence of patient attitudes and patient education. Pain 1992;50:257-262
Wilder-Smith CH, Spirig C, Krech T, Merki HS. Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 1992;4:885-891
Wilder-Smith CH, Merki HS. Tolerance to H2-receptor antagonists: an overview. Scand J Gastroenterol 1992;27(suppl 193):14-19
Borgeat A, Wilder-Smith OHG, Wilder-Smith CH, Forni M, Suter PM. Adjuvant propofol for refractory cisplatin-associated nausea and vomiting. Lancet 1992;340:679-680
Wilder-Smith CH. Gastroduodenal dysfunction as a cause of gastric bacterial overgrowth in patients undergoing mechanical ventilation of the lungs. Brit J Anaesth 1992;69:545
Merki HS, Halter F, Wilder-Smith CH. Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine. Gastroenterology 1993;105:748-754
Wilder-Smith CH. Pumpen und Ports in der Schmerztherapie. Schweiz Rundschau Med (Praxis) 1993;82:271-276
Wilder-Smith CH. Nicht-opioide in der Schmerztherapie: neue Perspektiven. Schweiz Rundschau Med (Praxis) 1993;82:289-292
Mazzucchelli L, Wilder-Smith CH, Ruchti C, Meyer-Wyss B, Merki HS. Gastrospirillum hominis in asymptomatic, healthy individuals. Dig Dis Sci 1993;38:2087-2089
Borgeat A, Wilder-Smith OHG, Wilder-Smith CH, Forni M, Suter PM. Propofol improves patient comfort during cisplatin chemotherapy. A pilot study. Oncology 1993;50:456-459
Borgeat A, Wilder-Smith OHG, Wilder-Smith CH, Rifat K, Chappuis P, Forni M. Refractory non-platin chemotherapy-associated nausea and vomiting: a pilot study with propofol. Cancer 1994;
Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol a µ-opioid agonist and monoamine reuptake blocker, and morphine for strong cancer-related pain. Ann Oncol 1994;5:141-146
Wilder-Smith CH, Wilder-Smith OH, Farschtschian M, Naji P. Epidural droperidol reduces the side-effects and duration of action of epidural sufentanil. Anesth Analg 1994;79:98-104
Wilder-Smith CH, Schuler L. Postoperative pain and analgesia. Nursing Times 1992;2:21
Wilder-Smith CH. Pumps and ports for treatment of pain: a review. Anesthesiology Digest 1994;32:142-145
Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994;106:60-64
Wilder-Smith CH, Merki HS, Wilder-Smith AE, Wilder-Smith OHG. Antisecretory and prokinetic agents for prophylaxis of perioperative acid aspiration syndrome: towards a more rational approach (review article). Eur J Gastro Hep 1994;6:1047-1052
Wilder-Smith CH, Bettschen HU, Merki HS. Individual and group dose-responses to intravenous omeprazole in the first 24h: pH-feedback-controlled and fixed-dose infusions. Br J Clin Pharmacol 1995;39:15-23
Wilder-Smith OHG, Kolletzki M, Wilder-Smith CH. The effect of sedative infusions of intravenous anesthetics on thermal pain detection thresholds. Anaesthesia 1995;50:218-222
Wilder-Smith CH. Co-editor: Antiemetische Therapie. H.H. Waldvogel, Thieme Verlag, Stuttgart 1995 (book)
Hufschmid E, Theurillat R, Wilder-Smith CH, Thormann. Characterisation of the genetic polymorphism of dihydrocodeine O-demethylation in man via analysis of urinary dihydrocodeine and dihydormorphine by micellar electrokinetic capillary chromatography. J Chromatogr 1996;678:43-51
Wilder-Smith CH, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 1997;43:71-75
Wilder-Smith CH, Knöpfli R, Wilder-Smith OHG. Perioperative magnesium infusion and postoperative pain. Acta Anaesthesiol Scand 1997;41:1023-1027
Wilder-Smith CH. Colon irritabile. Dolor 1997;4:1-4
Wilder-Smith CH, Wilder-Smith OHG, Farschtschian M, Naji P. Preoperative epidural tramadol: the effect of different doses on perioperative analgesia and antinociception. Acta Anaesth Scand 1998;42:299-305
Wilder-Smith CH. Clinical challenges of pain treatment in multimorbid patients, the older population and other risk groups. Drug Safety 1998;18:457-472
Wilder-Smith CH, Hufschmid E, Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydrocodeine. A cross-over study with extensive and quinidine-induced poor metabolisers. Br J Clin Pharmacol 1998;45:575-581
Wilder-Smith CH, Hill L, Osler W, O’Keefe SJD, Bornman P. The effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999;44:1107-1116
Wilder-Smith CH, Hill L, Wilkins J, Denny L. Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery. Anesthesiology 1999;91:639-647
Lehmann FS, Renner EL, Meyer-Wyss B, Wilder-Smith CH, Mazzucchelli L, Ruchti C, Drewe J, Beglinger C, Merki HS. Helicobacter pylori and gastric erosions. Results of a prevalence study in asymptomatic volunteers. Digestion 2000;62:82-86
Bütler TM, Wilder-Smith OHG, Wilder-Smith CH, Aebi S, Cerny T, Brenneisen R. Analgesic action of intravenous morphine-6-glucuronide in healthy volunteers. Brit J Anaesth 2000;84:97-99
Wilder-Smith CH, Hill L, Sparga K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAIDs: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001;91:23-31
Wilder-Smith CH. Opioids in cancer pain – which one is best? (editorial). Support Car Cancer 2001;9:71-72
Wilder-Smith CH. Co-editor: Analgetika, Antinozizepitva, Adjuvanzien. Handbuch für die Schmerzpraxis. H.H. Waldvogel, Springer Verlag, Berlin, 1996 (1st edition), 2001 (2nd edition) (book)
Wilder-Smith CH, Talbot I, Meier-Ruge W. Definition of normal morphometric neurohistology of the rectum. Eur J Gastro Hepatol 2002;14:1339-1342
Wilder-Smith CH, Wilder-Smith PEEB, Grosjean P, van den Bergh H, Woodtli A, Monnier P, Dorta A, Meister F, Wagnières G. Photoeradication of Helicobacter pylori using 5-aminolaevulinic acid: preliminary human studies. Lasers Surg Med 2002;13:18-22
Wilder-Smith C. Esomeprazole: effective first line therapy for acid related disorders. InPharma 2003;19:201-213Wilder-Smith CH, Hill L, Dyer RA, Torr G, Coetzee E. Postoperative sensitisation and pain after cesarean delivery and the effects of single IM doses of tramadol and diclofenac alone and in combination. Anesth Analg 2003;97:526-533
Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control compared with of lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003;68:184-188
Wilder-Smith CH, Schindler D, Lovblad L, Redmond SMS, Nirkko A. Brain functional magnetic resonance imaging of rectal pain and activation of descending endogenous inhibitory mechanisms in IBS patient subgroups and healthy controls. GUT 2004;53:1595-1601
Röhss K, Lind T, Wilder-Smith CH. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60:531-539
Wilder-Smith CH, Röhss K, Bondarov P, Hallerbäck B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg intravenously provides faster and more effective intragastric acid control than pantoprazole 40mg i.v.: results of a randomized study. Aliment Pharmacol Ther. 2004;20:1099-1104. (Erratum in: Aliment Pharmacol Ther. 2005;21:101)
Wilder-Smith CH, Hill L, Laurent S. Postamputation pain and sensory changes: characteristics and responses to treatment with tramadol, amitryptiline and placebo. Anesthesiology 2005;103:619-628.
Wilder-Smith CH, Bondarov P, Lundgren M, Niazi M, Rohss K, Ahlbom H, Nyman L. Intravenous Esomeprazole (40mg and 20mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomised clinical studies. Eur J Gastroenterol Hepatol. 2005;17:191-197
Swaisland H, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, Duvauchelle T. Clinical pharmacokinetics of gefitinib, a selective oral epidermal growth factor receptor tyrosinase kinase inhibitor. Clinical Pharmacokinetics 2005;44:1165-1177
Röhss K, Wilder-Smith CH, Jansson L. Intragastric acid control with maintenance dose PPIs: esomeprazole 20 mg provides more effective intragastric acid control than lansoprazole 15 mg, rabeprazole 10mg or pantoprazole 20mg in healthy volunteers. Clinical Drug Investigation 2004;24:1-7
Wilder-Smith CH, Jonzon B, Fornstedt-Wallin B, Hedman A, Karlsson P. Dose-effect comparisons of the CINOD AZDZ3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scand J Gastro Hepatol 2006;41:264-273Wilder-Smith CH. Röhss K, Bondarov P, Lundin C, Niazi M, Nilsson-Pieschl C, Ahlbom H. Intravenous esomeprazole 40mg is effective at controlling intragastric acid whether given as a 3-minute injection or 30-minute infusion. Clinical Drug Investigation 2005;25:517-525
Wilder-Smith P, Wilder-Smith CH, Hammer-Wilson MJ, Nguyen V, Truong M, Jequinto G, Zhang J, Jung WG, Chen Z. A novel approach to the non-invasive quantification of enamel erosion and demineralization. Accepted 2006
Wilson M, Gray R, Wilder-Smith P, Meister F, Osann K, Wilder-Smith CH. Fluorescence diagnostics of Helicobacter pylori infected human gastric mucosa: establishing technique and validity. Accepted Scand J Gastroenterol 2006
Wilder-Smith CH, Hill L, Wilkins J, Denny L. Abdominal hysterectomies and irritable bowel syndrome. Submitted 2006
Lussi A, Wilder-Smith CH. Dentale Erosionen bei Kindern und Jugendlichen. Schweiz Monatsschr Zahnmed 2006;116:917-927
Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole (20, 40, 80mg) provides more effective intragastric acid control than lansoprazole (15, 30, 60mg) in healthy volunteers. Accepted Scand J Gastroenterol 2006
Song GH, Venkatraman V, Ho KY, Chee MWL, Yeoh KG, Wilder-Smith CH. Anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in Irritable Bowel Syndrome patients and controls. Pain 2006;126:79-90
Wilder-Smith CH, Yap-Robert J. Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with Irritable Bowel Syndrome (IBS). Submitted 2006
Wilder-Smith CH. Predicting clinical pain and pain responses to opioids. A Review. Eur J Pain 2006 (Accepted)
Wilder-Smith CH, Lind T, Lundin C, Naucler E, Nilsson-Pieschl C, Rohss K. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2006 (accepted)
Rohss K, Sandstrom M, Ekeklund M, Hasselgren G, Franzen S, Wilder-Smith C, Hassar-Alin M, Sagar M. Pharmacodynamic and pharmacokinetic properties of the potassium-competititve acid blocker, AZD0865, in healthy subjects. Submitted 2006.
Rohss K, Wilder-Smith C, Kilhamn J, Svensson M, Lind T. Suppression of gastric acid with i.v. esomprazole or omeprazole: results of three studies in healthy subjects. Accepted 2006